MedPath

Clinical and Radiographic Evaluation of Biodentine in Revascularization of Non-Vital Immature Teeth

A study comparing the clinical and radiographic outcomes of using Biodentine versus white Mineral Trioxide Aggregate as coronal plug materials in the revascularization of non-vital immature teeth found no significant difference in success rates or root length increase, but a notable difference in tooth discoloration.

Objective: To assess clinically and radiographically the effect of using two types of coronal plug materials in revascularization of non-vital immature teeth.
Methods: A total of 26 necrotic immature permanent anterior teeth were enrolled for pulp revascularization using a double antibiotic mix for root canal disinfection. They were randomly divided into two groups based on the coronal plug materials used: Biodentine (Group I) and white Mineral Trioxide Aggregate (Group II; n = 13). Clinical and radiographic assessments were performed after 3, 6, 9, and 12 months.
Results: The study found no statistically significant difference in the overall clinical successes and percentage of increase in root length between the two groups (P > 0.05). However, there was a significant difference in the distribution of discoloration between the two groups, with one case reported in Group I and seven cases in Group II (P = 0.01).
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Clinical and Radiographic Evaluation of Silver Diamine Fluoride Versus Mineral Trioxide Aggregate in Indirect Pulp Capping

A randomized clinical trial compared the effectiveness of Silver Diamine Fluoride (SDF) and Mineral Trioxide Aggregate (MTA) in indirect pulp capping (IPC) for first permanent molars with deep carious lesions. Both materials showed a 100% clinical and radiographic success rate after 12 months, with no significant differences in dentin bridge thickness. The study highlights the potential of SDF as a cost-effective alternative to MTA for IPC in permanent teeth, despite the need for further research.

Intratracheal Budesonide Fails to Improve Outcomes in Preterm Infants

A recent clinical trial found that intratracheal budesonide mixed with surfactant did not significantly improve survival free of bronchopulmonary dysplasia (BPD) in extremely preterm infants.
The study, involving 1059 infants born before 28 weeks' gestation, showed no clear difference in outcomes compared to surfactant-only treatment.

Partial Breast Irradiation Shows Acceptable Cosmetic Outcomes in Early Breast Cancer Trial

A phase II trial found that partial breast irradiation (PBI) with either 30 Gy or 27.5 Gy resulted in acceptable adverse cosmesis in early breast cancer patients.
At 2 years, both schedules met acceptability criteria based on photographic and nurse assessments of adverse cosmesis.

CT-P13 Subcutaneous Formulation Shows Comparable Pharmacokinetics and Safety via Autoinjector and Pre-filled Syringe

A study published in *Clinical and Translational Science* found that the pharmacokinetics and safety of subcutaneous CT-P13 (Zymfentra), an infliximab biosimilar, are comparable whether administered via autoinjector or pre-filled syringe.
The open-label, single-dose study included 147 healthy participants who were randomized to receive CT-P13 either through autoinjection or pre-filled syringe, with comparable drug exposure observed in both groups.

Repeated Preheating of Bulk Fill Composite Does Not Compromise Dental Restoration Integrity

A randomized clinical trial evaluated the impact of repeated preheating cycles on bulk fill composite restorations over 24 months.
The study found no statistically significant differences in clinical performance between non-heated and preheated composite groups.

Benitec Biopharma's BB-301 Gene Therapy Shows Swallowing Improvement in OPMD Patients

Benitec Biopharma's BB-301 gene therapy demonstrated clinically meaningful improvements in swallowing for OPMD patients in a Phase 1b/2a trial.
The first patient showed a 35% reduction in the Sydney Swallow Questionnaire (SSQ) score after 270 days of treatment.

Gemcitabine Shows Comparable Efficacy to Mitomycin C in Non-Muscle Invasive Bladder Cancer

A randomized phase II trial compared intravesical gemcitabine to mitomycin C after resection of non-muscle invasive bladder cancer (NMIBC).
Recurrence rates and time to recurrence were similar between gemcitabine and mitomycin C groups after one year of follow-up.

Light-Activated Therapy Shows Promise in Improving Oral Health for Adolescents with Braces

A clinical trial is underway to assess light-activated antibacterial therapy's effectiveness in improving plaque control for adolescents with braces.
The Lumoral device, combining antibacterial blue and red light with a photosensitive mouth rinse, aims to reduce harmful bacteria and plaque buildup.

REC-CAGEFREE I: Drug-Coated Balloon Angioplasty Fails to Meet Noninferiority Criteria Compared to DES

The REC-CAGEFREE I trial assessed paclitaxel-coated balloon (DCB) angioplasty against drug-eluting stents (DES) in patients with de novo coronary artery lesions.
The study found DCB angioplasty did not meet noninferiority criteria compared to DES for cardiovascular outcomes at 2 years, showing potential inferiority.

Clinical and Radiographic Evaluation of Mineral Trioxide Aggregate and Human Amniotic Membrane in Primary Molar Teeth

A study comparing the outcomes of pulpotomy using Mineral Trioxide Aggregate (MTA) and Human Amniotic Membrane (HAM) in primary molar teeth found both materials to have 100% clinical success. However, HAM showed a significant reduction in periodontal ligament widening over time, suggesting it as a favorable alternative to MTA for pulpotomy in primary teeth.

Reference News

[1]
Clinical and radiographic evaluation of Biodentine ...
pubmed.ncbi.nlm.nih.gov · Jul 10, 2019

Study on 26 necrotic immature teeth revascularized with a double antibiotic mix, comparing Biodentine (Group I) and whit...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy